Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Intraperitoneal chemotherapy prolongs survival for women with advanced ovarian cancer
February 2nd, 2006
A study featured in Gynecologic Oncology examines the challenges associated with the administration of intra-abdominal chemotherapy, also known as intraperitoneal (IP) chemotherapy. This is a companion study to a paper released in the New England Journal of Medicine showing longer survival for women who received IP chemotherapy compared with those who received the standard intravenous (IV) regimen. The New England Journal of Medicine study, "Intravenous Cisplatin and Paclitaxel Versus an Intensive Regimen of Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Stage III Ovarian Cancer: A Gynecologic...
Source: Women's Health Weekly (2006-02-02)
|
